Edwards Lifesciences (EW) Tops Q4 EPS by 3c, Offers Q1 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Edwards Lifesciences Reports Fourth Quarter Results
February 1, 2017 4:15 PM ESTIRVINE, Calif., Feb. 1, 2017 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended December 31, 2016.Â
Fourth Quarter and Recent Highlights:
Sales grew 14 percent to $768 million; underlying1 sales were up 15 percent Global Transcatheter Heart Valve Therapy (THVT) sales grew 29 percent to $432 million U.S. THVT sales were up 38 percent EPS was $0.73, an increase of 14... More